Chip-based digital PCR as a direct quantification method for residual DNA in mRNA drugs

Fan, Wenchao; Zhao, Lan; Yu, Lei; Zhou, Yong

doi:10.1016/j.jpba.2023.115837

Journal of Pharmaceutical and Biomedical Analysis

2024

DOI: 10.1016/j.jpba.2023.115837

|View full text |Cite

Chip-based digital PCR as a direct quantification method for residual DNA in mRNA drugs

Wenchao Fan,

Lan Zhao,

Lei Yu

et al.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2024

Publication Types

Select...

Article1

Relationship

Self Cite0

Independent1

Authors

Journals

Cited by 1 publication

References 14 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

Research progress of CTC, ctDNA, and EVs in cancer liquid biopsy

Wang,

Lin

et al. 2024

Front. Oncol.

View full text Add to dashboard Cite

Circulating tumor cells (CTCs), circulating tumor DNA (ctDNA), and extracellular vehicles (EVs) have received significant attention in recent times as emerging biomarkers and subjects of transformational studies. The three main branches of liquid biopsy have evolved from the three primary tumor liquid biopsy detection targets—CTC, ctDNA, and EVs—each with distinct benefits. CTCs are derived from circulating cancer cells from the original tumor or metastases and may display global features of the tumor. ctDNA has been extensively analyzed and has been used to aid in the diagnosis, treatment, and prognosis of neoplastic diseases. EVs contain tumor-derived material such as DNA, RNA, proteins, lipids, sugar structures, and metabolites. The three provide different detection contents but have strong complementarity to a certain extent. Even though they have already been employed in several clinical trials, the clinical utility of three biomarkers is still being studied, with promising initial findings. This review thoroughly overviews established and emerging technologies for the isolation, characterization, and content detection of CTC, ctDNA, and EVs. Also discussed were the most recent developments in the study of potential liquid biopsy biomarkers for cancer diagnosis, therapeutic monitoring, and prognosis prediction. These included CTC, ctDNA, and EVs. Finally, the potential and challenges of employing liquid biopsy based on CTC, ctDNA, and EVs for precision medicine were evaluated.

show abstract

Research progress of CTC, ctDNA, and EVs in cancer liquid biopsy

Wang,

Lin

et al. 2024

Front. Oncol.

View full text Add to dashboard Cite

show abstract

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

customersupport@researchsolutions.com

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

Chip-based digital PCR as a direct quantification method for residual DNA in mRNA drugs

Cited by 1 publication

References 14 publications

Research progress of CTC, ctDNA, and EVs in cancer liquid biopsy

Research progress of CTC, ctDNA, and EVs in cancer liquid biopsy

Contact Info

Product

Resources

About